L
LatchBio
AI agents and data infrastructure for biology research
About LatchBio
LatchBio is a San Francisco-based company that builds software infrastructure for biological research, with a current focus on researching, evaluating and improving AI agents for biology. The company was founded in 2021 by Alfredo Andere, Kenny Workman and Kyle Giffin, who met as undergraduates at the University of California, Berkeley. Its stated mission is to build and disseminate the data infrastructure for what it calls the biocomputing revolution.
The company began with a web-based platform that lets biologists store, process and visualize experimental data without writing code or setting up cloud infrastructure. Researchers can import files from their existing data stacks, run popular bioinformatics pipelines and visualization tools such as RNA-seq, CRISPR analysis and protein structure prediction, and work with results through a browser. Bioinformaticians can publish workflows through the LatchBio SDK, which automatically generates no-code interfaces for wet-lab scientists, while serverless infrastructure handles storage and compute at scale.
LatchBio has since extended its work into agentic AI for the life sciences. It publishes a series of verifiable benchmarks that test how well AI agents analyze real biological data, covering areas such as single-cell and spatial biology, epigenomics, metagenomics, genetic variant interpretation, oncology, neuroscience, rare disease diagnosis and therapeutic discovery for antibodies, oligonucleotides and small molecules. A dedicated biosecurity programme evaluates agent capabilities and refusals in pathogen surveillance, structural risk assessment and countermeasure design.
The company serves pharmaceutical, biotechnology and academic research teams and sells its software on a subscription basis. It is hiring scientists, engineers and operators in San Francisco and remotely.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 41
- Open positions
- 9
- Dealroom signal
- 95.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Drug Development, Synthetic Biology, Sustainable Development Goals, Tech for Biotech and Pharma, Biotech and Pharma, Climate Tech, Techbio, Techbio Drug Discovery, Digital Pharma
- Business model
- SaaS
- Client focus
- B2B
News
Open roles
| Role | Team | Location | Posted |
|---|---|---|---|
| Member of Technical Staff, Medicinal Chemistry | San Francisco, US | 2d ago | |
| Member of Technical Staff, Molecular DesignDesign | Design | San Francisco, US | 2d ago |
| Member of Technical Staff, Experimental Biology & Assay Development | San Francisco, US | 2d ago | |
| Member of Technical Staff, Chemistry | San Francisco, US | 2d ago | |
| Member of Technical Staff, Translational Science | San Francisco, US | 2d ago | |
| Member of Technical Staff, Clinical DevelopmentClinical | Clinical | San Francisco, US | 2d ago |
| Member of Technical Staff, Clinical OperationsClinical | Clinical | San Francisco, US | 2d ago |
| Member of Technical Staff, Clinical Data & Statistical ProgrammingClinical | Clinical | San Francisco, US | 2d ago |
| Member of Technical Staff, Biostatistics & Trial DesignDesign | Design | San Francisco, US | 2d ago |
| AI Biologist - Gene Therapy Discovery | San Francisco (preferred) · Remote | 3d ago | |
| AI Biologist - Cell Therapy Discovery | San Francisco (preferred) · Remote | 3d ago | |
| AI Biologist - Metabolomics | San Francisco (preferred) · Remote | 3d ago |
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Apr 2026 | $130M | $500M | Undisclosed | ↗ |
| SERIES AOther financing | Jun 2022 | $28M | $112M | Haystack · Caffeinated Capital · Lux Capital · Hummingbird Ventures | ↗ |
Growth signals
Latest recorded traffic for LatchBio is 29K monthly website visits, up 81.3% over the last three months. LatchBio's team grew 173.3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
LatchBio in the San Francisco ecosystem
The LatchBio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed6 investors entered at this stage
Swift Ventures
Lux Capital
General Catalyst
Haystack
Alec Nielsen
Fifty Years
Series A3 investors entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
See LatchBio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.











